Sledge Jr. GW, et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. LBA6_PR. ESMO 2019. 28 sep.-1 okt. 2019, Barcelona, Spanje.
HRQOL en cognitieve functie na lomustine-temozolomide versus temozolomide
dec 2019 | Neuro-oncologie